Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. / Bronsveld, Heleen K; ter Braak, Bas; Karlstad, Øystein; Vestergaard, Peter; Starup-Linde, Jakob; Bazelier, Marloes T; De Bruin, Marie L; de Boer, Anthonius; Siezen, Christine L E; van de Water, Bob; van der Laan, Jan Willem; Schmidt, Marjanka K.

I: Breast cancer research : BCR, Bind 17, 2015, s. 100.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Bronsveld, HK, ter Braak, B, Karlstad, Ø, Vestergaard, P, Starup-Linde, J, Bazelier, MT, De Bruin, ML, de Boer, A, Siezen, CLE, van de Water, B, van der Laan, JW & Schmidt, MK 2015, 'Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence', Breast cancer research : BCR, bind 17, s. 100. https://doi.org/10.1186/s13058-015-0611-2

APA

Bronsveld, H. K., ter Braak, B., Karlstad, Ø., Vestergaard, P., Starup-Linde, J., Bazelier, M. T., ... Schmidt, M. K. (2015). Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast cancer research : BCR, 17, 100. https://doi.org/10.1186/s13058-015-0611-2

Vancouver

Bronsveld HK, ter Braak B, Karlstad Ø, Vestergaard P, Starup-Linde J, Bazelier MT o.a. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast cancer research : BCR. 2015;17:100. https://doi.org/10.1186/s13058-015-0611-2

Author

Bronsveld, Heleen K ; ter Braak, Bas ; Karlstad, Øystein ; Vestergaard, Peter ; Starup-Linde, Jakob ; Bazelier, Marloes T ; De Bruin, Marie L ; de Boer, Anthonius ; Siezen, Christine L E ; van de Water, Bob ; van der Laan, Jan Willem ; Schmidt, Marjanka K. / Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. I: Breast cancer research : BCR. 2015 ; Bind 17. s. 100.

Bibtex

@article{ff0a370ae21948eda6a8f26464df3775,
title = "Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence",
abstract = "INTRODUCTION: Several studies have suggested that anti-diabetic insulin analogue treatment might increase cancer risk. The aim of this study was to review the postulated association between insulin and insulin analogue treatment and breast cancer development, and plausible mechanisms.METHOD: A systematic literature search was performed on breast cell-line, animal and human studies using the key words 'insulin analogue' and 'breast neoplasia' in MEDLINE at PubMed, EMBASE, and ISI Web of Science databases. A quantitative and qualitative review was performed on the epidemiological data; due to a limited number of reported estimates, a meta-analysis was performed for glargine only. A comprehensive overview was composed for in vitro and animal studies. Protein and gene expression was analysed for the cell lines most frequently used in the included in vitro studies.RESULTS: In total 16 in vitro, 5 animal, 2 in vivo human and 29 epidemiological papers were included. Insulin AspB10 showed mitogenic properties in vitro and in animal studies. Glargine was the only clinically available insulin analogue for which an increased proliferative potential was found in breast cancer cell lines. However, the pooled analysis of 13 epidemiological studies did not show evidence for an association between insulin glargine treatment and an increased breast cancer risk (HR 1.04; 95 {\%} CI 0.91-1.17; p=0.49) versus no glargine in patients with diabetes mellitus. It has to be taken into account that the number of animal studies was limited, and epidemiological studies were underpowered and suffered from methodological limitations.CONCLUSION: There is no compelling evidence that any clinically available insulin analogue (Aspart, Determir, Glargine, Glulisine or Lispro), nor human insulin increases breast cancer risk. Overall, the data suggests that insulin treatment is not involved in breast tumour initiation, but might induce breast tumour progression by up regulating mitogenic signalling pathways.",
keywords = "Animals, Breast Neoplasms, Cell Line, Tumor, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin Glargine, MCF-7 Cells, Risk, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't",
author = "Bronsveld, {Heleen K} and {ter Braak}, Bas and {\O}ystein Karlstad and Peter Vestergaard and Jakob Starup-Linde and Bazelier, {Marloes T} and {De Bruin}, {Marie L} and {de Boer}, Anthonius and Siezen, {Christine L E} and {van de Water}, Bob and {van der Laan}, {Jan Willem} and Schmidt, {Marjanka K}",
year = "2015",
doi = "10.1186/s13058-015-0611-2",
language = "English",
volume = "17",
pages = "100",
journal = "Breast Cancer Research (Online Edition)",
issn = "1465-5411",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence

AU - Bronsveld, Heleen K

AU - ter Braak, Bas

AU - Karlstad, Øystein

AU - Vestergaard, Peter

AU - Starup-Linde, Jakob

AU - Bazelier, Marloes T

AU - De Bruin, Marie L

AU - de Boer, Anthonius

AU - Siezen, Christine L E

AU - van de Water, Bob

AU - van der Laan, Jan Willem

AU - Schmidt, Marjanka K

PY - 2015

Y1 - 2015

N2 - INTRODUCTION: Several studies have suggested that anti-diabetic insulin analogue treatment might increase cancer risk. The aim of this study was to review the postulated association between insulin and insulin analogue treatment and breast cancer development, and plausible mechanisms.METHOD: A systematic literature search was performed on breast cell-line, animal and human studies using the key words 'insulin analogue' and 'breast neoplasia' in MEDLINE at PubMed, EMBASE, and ISI Web of Science databases. A quantitative and qualitative review was performed on the epidemiological data; due to a limited number of reported estimates, a meta-analysis was performed for glargine only. A comprehensive overview was composed for in vitro and animal studies. Protein and gene expression was analysed for the cell lines most frequently used in the included in vitro studies.RESULTS: In total 16 in vitro, 5 animal, 2 in vivo human and 29 epidemiological papers were included. Insulin AspB10 showed mitogenic properties in vitro and in animal studies. Glargine was the only clinically available insulin analogue for which an increased proliferative potential was found in breast cancer cell lines. However, the pooled analysis of 13 epidemiological studies did not show evidence for an association between insulin glargine treatment and an increased breast cancer risk (HR 1.04; 95 % CI 0.91-1.17; p=0.49) versus no glargine in patients with diabetes mellitus. It has to be taken into account that the number of animal studies was limited, and epidemiological studies were underpowered and suffered from methodological limitations.CONCLUSION: There is no compelling evidence that any clinically available insulin analogue (Aspart, Determir, Glargine, Glulisine or Lispro), nor human insulin increases breast cancer risk. Overall, the data suggests that insulin treatment is not involved in breast tumour initiation, but might induce breast tumour progression by up regulating mitogenic signalling pathways.

AB - INTRODUCTION: Several studies have suggested that anti-diabetic insulin analogue treatment might increase cancer risk. The aim of this study was to review the postulated association between insulin and insulin analogue treatment and breast cancer development, and plausible mechanisms.METHOD: A systematic literature search was performed on breast cell-line, animal and human studies using the key words 'insulin analogue' and 'breast neoplasia' in MEDLINE at PubMed, EMBASE, and ISI Web of Science databases. A quantitative and qualitative review was performed on the epidemiological data; due to a limited number of reported estimates, a meta-analysis was performed for glargine only. A comprehensive overview was composed for in vitro and animal studies. Protein and gene expression was analysed for the cell lines most frequently used in the included in vitro studies.RESULTS: In total 16 in vitro, 5 animal, 2 in vivo human and 29 epidemiological papers were included. Insulin AspB10 showed mitogenic properties in vitro and in animal studies. Glargine was the only clinically available insulin analogue for which an increased proliferative potential was found in breast cancer cell lines. However, the pooled analysis of 13 epidemiological studies did not show evidence for an association between insulin glargine treatment and an increased breast cancer risk (HR 1.04; 95 % CI 0.91-1.17; p=0.49) versus no glargine in patients with diabetes mellitus. It has to be taken into account that the number of animal studies was limited, and epidemiological studies were underpowered and suffered from methodological limitations.CONCLUSION: There is no compelling evidence that any clinically available insulin analogue (Aspart, Determir, Glargine, Glulisine or Lispro), nor human insulin increases breast cancer risk. Overall, the data suggests that insulin treatment is not involved in breast tumour initiation, but might induce breast tumour progression by up regulating mitogenic signalling pathways.

KW - Animals

KW - Breast Neoplasms

KW - Cell Line, Tumor

KW - Diabetes Mellitus, Type 2

KW - Female

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin Glargine

KW - MCF-7 Cells

KW - Risk

KW - Journal Article

KW - Meta-Analysis

KW - Research Support, Non-U.S. Gov't

U2 - 10.1186/s13058-015-0611-2

DO - 10.1186/s13058-015-0611-2

M3 - Journal article

VL - 17

SP - 100

JO - Breast Cancer Research (Online Edition)

JF - Breast Cancer Research (Online Edition)

SN - 1465-5411

ER -

ID: 164617857